Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

MDGL

Madrigal Pharmaceuticals Inc

May 03 • 04:00PM ET

229.84

Dollar change +13.79
Percentage change 6.38	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBR IWM VXF IWO IBB SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-19.94	Insider Own	18.63%	Shs Outstand	19.88M	Perf Week	18.88%
Market Cap	4.89B	Forward P/E	-	EPS next Y	-14.40	Insider Trans	4.06%	Shs Float	17.32M	Perf Month	-4.81%
Income	-373.63M	PEG	-	EPS next Q	-6.22	Inst Own	88.00%	Short Float	19.67%	Perf Quarter	4.34%
Sales	0.00M	P/S	-	EPS this Y	-16.87%	Inst Trans	-1.64%	Short Ratio	5.56	Perf Half Y	68.39%
Book/sh	20.39	P/B	11.27	EPS next Y	38.34%	ROA	-74.49%	Short Interest	3.41M	Perf Year	-24.59%
Cash/sh	29.80	P/C	7.71	EPS next 5Y	0.00%	ROE	-123.98%	52W Range	119.76 - 313.11	Perf YTD	-0.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-55.24%	ROI	-71.58%	52W High	-26.59%	Beta	-0.44
Dividend TTM	-	Quick Ratio	5.38	Sales past 5Y	0.00%	Gross Margin	-	52W Low	91.92%	ATR (14)	13.16
Dividend Ex-Date	-	Current Ratio	5.38	EPS Y/Y TTM	-15.71%	Oper. Margin	0.00%	RSI (14)	53.13	Volatility	5.78% 5.27%
Employees	376	Debt/Eq	0.29	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.47	Target Price	377.07
Option/Short	Yes / Yes	LT Debt/Eq	0.29	EPS Q/Q	-13.93%	Payout	-	Rel Volume	0.72	Prev Close	216.05
Sales Surprise	-	EPS Surprise	-8.42%	Sales Q/Q	-	Earnings	May 07 BMO	Avg Volume	612.84K	Price	229.84
SMA20	3.29%	SMA50	-4.53%	SMA200	14.20%	Trades		Volume	441,615	Change	6.38%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135
May-05-20	Initiated	Chardan Capital Markets	Buy	$205
Jan-30-20	Initiated	Canaccord Genuity	Buy	$198
Jan-09-20	Upgrade	UBS	Neutral → Buy	$125 → $127
Nov-07-19	Reiterated	H.C. Wainwright	Buy	$225 → $215

Show Previous Ratings

Apr-24-24 04:00PM	Madrigal Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire) -6.29%
Apr-23-24 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Apr-16-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:28PM	Latest Insider Selling in April 2024: 10 Stocks to Watch (Insider Monkey)
08:00AM	Loading…
Apr-09-24 08:00AM	Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Apr-05-24 07:15AM	Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics (Motley Fool)
Apr-04-24 01:55AM	Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares (GuruFocus.com)
Apr-03-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:45AM	1 No-Brainer Growth Stock to Buy Now (Motley Fool)
Apr-01-24 09:09PM	The 3 Best Biotech Stocks to Buy in April 2024 (InvestorPlace)
09:59AM	ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 09:00AM	Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
04:43AM	Loading…
04:43AM	Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? (Motley Fool)
Mar-26-24 09:53AM	Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock (Motley Fool)
Mar-22-24 06:15AM	This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? (Motley Fool)
Mar-19-24 05:50AM	Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? (Motley Fool) -6.20%
Mar-18-24 11:58PM	Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering (GlobeNewswire)
08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
04:47PM	UPDATE 1-Madrigal plans $500 million fund raising to prepare for NASH drug launch (Reuters)
04:12PM	Madrigal commences $500 million public offering of common stock (Reuters)
04:04PM	Madrigal Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
03:15PM	Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark (Investor's Business Daily)
07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
05:50AM	Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? (Motley Fool)
Mar-15-24 04:35PM	Wegovy and Zepbound Cast Shadow Over Madrigals Liver Drug (Barrons.com) +11.00%
04:14PM	Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment (Investor's Business Daily)
03:50PM	Loading…
03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video)
02:34PM	Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment (The Wall Street Journal)
01:45PM	Madrigal Pharmaceuticals Soars After Getting FDA Approval for Liver-Scarring Treatment (Investopedia)
12:56PM	Top Stock Movers Now: Adobe, Ulta Beauty, Jabil, and More (Investopedia)
12:09PM	US STOCKS-Wall St slides as inflation woes dampen rate-cut bets (Reuters)
10:17AM	MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today (InvestorPlace)
10:01AM	Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars. (Barrons.com)
09:30AM	Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH (Zacks)
07:45AM	Madrigal Stock Soars More Than 25% After FDA Approved First In MASH Treatment (Investor's Business Daily)
05:35AM	Madrigal, FDA approval in hand, outlines plan to sell MASH drug (BioPharma Dive)
Mar-14-24 04:25PM	Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH (Investor's Business Daily) -10.77%
04:15PM	Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
12:11PM	Madrigal wins FDA approval of first drug for MASH (BioPharma Dive)
Mar-09-24 05:52AM	Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
Mar-06-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-24 08:00AM	Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis (GlobeNewswire)
06:03AM	1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? (Motley Fool)
Feb-28-24 07:01AM	Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer (GlobeNewswire) +6.02%
07:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:45AM	Madrigal: Q4 Earnings Snapshot (Associated Press Finance)
Feb-26-24 04:04PM	Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study (Investor's Business Daily)
10:52AM	Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena (Investor's Business Daily)
Feb-23-24 05:43AM	1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street (Motley Fool)
Feb-21-24 08:00AM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.33%
Feb-08-24 08:00AM	Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine (GlobeNewswire) -9.11%
Feb-06-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.28%
11:29AM	Why Eli Lilly Deserves to Unseat Tesla Among the Magnificent Seven (The Wall Street Journal)
11:28AM	Madrigal Pharmaceuticals Stock Shows Rising Relative Strength (Investor's Business Daily)
Jan-29-24 08:00AM	Madrigal Pharmaceuticals Announces Additions to Its Leadership Team (GlobeNewswire)
02:59AM	2 Rising Biotechs That Could Become the Next Novo Nordisk (Motley Fool)
Jan-22-24 08:00AM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:29AM	2 Stocks That Could Soar This Year: Are They Buys? (Motley Fool)
Jan-04-24 08:00AM	Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference (GlobeNewswire)
01:21AM	5 FDA decisions to watch in the first quarter (BioPharma Dive)
Jan-03-24 04:30PM	Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.58%
Dec-30-23 06:50AM	3 Stocks That Could Be Monster Winners in 2024 (Motley Fool)
Dec-22-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.74%
Dec-19-23 01:02PM	Senior VP Robert Waltermire Sells 4,000 Shares of Madrigal Pharmaceuticals Inc (MDGL) (GuruFocus.com)
10:16AM	11 Stocks Insiders and Billionaires Are Crazy About (Insider Monkey)
Dec-15-23 11:01PM	Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals Inc (GuruFocus.com)
Dec-07-23 08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Nov-27-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-24-23 10:00AM	Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-21-23 08:00AM	Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer (GlobeNewswire)
Nov-17-23 10:46AM	Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating (Investor's Business Daily)
Nov-16-23 03:03PM	Baker Bros. Advisors LP Bolsters Position in Madrigal Pharmaceuticals Inc (GuruFocus.com)
Nov-15-23 04:45PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-23 10:56AM	The 3 Most Undervalued Biotech Stocks to Buy: November 2023 (InvestorPlace) +7.17%
Nov-13-23 04:40PM	Billionaire John Paulson's Messy Divorce and Top 5 Stock Picks (Insider Monkey) +5.16%
Nov-10-23 08:00AM	Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health (GlobeNewswire)
07:30AM	Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer (GlobeNewswire)
Nov-07-23 04:54AM	Madrigal Pharmaceuticals Inc (MDGL) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
Nov-06-23 08:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
06:29AM	Madrigal: Q3 Earnings Snapshot (Associated Press Finance)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-02-23 04:05PM	Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
Oct-17-23 09:53AM	2 Risky Stocks With Massive Potential (Motley Fool)
Oct-12-23 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:49AM	Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment? (Entrepreneur: Stocks)
Oct-02-23 11:51AM	Madrigal (MDGL) to Raise Capital Via Public Offering of $500M (Zacks)
Sep-29-23 12:41PM	5 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-28-23 10:30PM	Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering (GlobeNewswire)
04:01PM	Madrigal Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Sep-27-23 09:53AM	Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon. (Motley Fool)
Sep-25-23 08:08PM	Goldman Sachs Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Sep-21-23 09:25AM	Weight-Loss Drugs Like Wegovy Are Bad News for These Stocks (Barrons.com)
09:25AM	Weight-Loss Drugs Like Ozempic Are Bad News for These Stocks (Barrons.com)

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRIEDMAN PAUL A	Director	Apr 08 '24	Option Exercise	9.45	26,270	248,251	212,005	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Option Exercise	9.45	2,676	25,288	461,675	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Sale	246.19	26,270	6,467,491	185,735	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Sale	245.99	2,676	658,258	458,999	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Option Exercise	9.45	27,613	260,943	213,348	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Option Exercise	9.45	27,506	259,932	486,505	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Sale	243.40	27,613	6,721,081	185,735	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Sale	243.36	27,506	6,693,790	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Option Exercise	9.45	18,710	176,810	204,445	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Option Exercise	9.45	18,537	175,175	477,536	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Sale	242.96	18,710	4,545,721	185,735	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Sale	242.91	18,537	4,502,823	458,999	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Option Exercise	9.45	27,845	263,135	486,844	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Option Exercise	9.45	27,407	258,996	213,142	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Sale	245.14	27,845	6,825,976	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Sale	245.12	27,407	6,718,002	185,735	Apr 05 08:50 PM
BATE KENNETH	Director	Apr 02 '24	Option Exercise	105.08	11,212	1,178,157	12,410	Apr 03 08:44 PM
Daly James M	Director	Apr 02 '24	Option Exercise	105.08	10,912	1,146,633	12,110	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 02 '24	Sale	244.49	11,212	2,741,219	1,198	Apr 03 08:44 PM
Daly James M	Director	Apr 02 '24	Sale	244.51	10,912	2,668,087	1,198	Apr 03 08:41 PM
Daly James M	Director	Apr 01 '24	Option Exercise	100.79	21,577	2,174,711	22,775	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 01 '24	Option Exercise	57.96	21,277	1,233,187	22,475	Apr 03 08:44 PM
Levy Richard S	Director	Apr 01 '24	Option Exercise	63.92	11,000	703,160	21,298	Apr 03 08:47 PM
Daly James M	Director	Apr 01 '24	Sale	257.24	21,577	5,550,544	1,198	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 01 '24	Sale	257.26	21,277	5,473,779	1,198	Apr 03 08:44 PM
Levy Richard S	Director	Apr 01 '24	Sale	257.48	11,000	2,832,335	10,298	Apr 03 08:47 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Sale	238.50	2,000	477,000	5,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 14 '23	Buy	228.32	20,633	4,710,893	1,793,403	Dec 14 06:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Sale	232.50	2,000	465,000	5,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Option Exercise	87.92	2,500	219,800	8,167	Dec 14 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 13 '23	Buy	219.39	81,159	17,805,684	1,774,294	Dec 14 06:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Sale	225.40	2,500	563,500	5,667	Dec 14 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Option Exercise	87.92	1,300	114,296	6,967	Dec 14 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 12 '23	Buy	218.31	34,578	7,548,616	1,699,129	Dec 14 06:09 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Sale	217.85	1,300	283,200	5,667	Dec 14 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Option Exercise	87.09	1,000	87,090	16,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Sale	227.33	1,000	227,330	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Option Exercise	81.16	1,800	146,090	16,801	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Sale	218.87	1,800	393,964	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Option Exercise	73.75	3,000	221,250	18,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Sale	204.58	3,000	613,730	15,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Option Exercise	73.75	4,000	295,000	19,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Sale	199.19	4,000	796,750	15,001	Dec 01 04:30 PM
BAKER BROS. ADVISORS LP	Director	Nov 21 '23	Buy	188.47	64,350	12,128,340	1,667,104	Nov 21 06:15 PM
BAKER BROS. ADVISORS LP	Director	Nov 20 '23	Buy	185.74	20,709	3,846,575	1,607,668	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 17 '23	Buy	174.70	46,370	8,100,704	1,588,541	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 15 '23	Buy	161.97	15,199	2,461,721	1,545,775	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 14 '23	Buy	154.00	37,660	5,799,653	1,500,227	Nov 15 05:12 PM
BAKER BROS. ADVISORS LP	Director	Nov 14 '23	Buy	156.42	34,188	5,347,837	1,531,757	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 13 '23	Buy	143.21	69,839	10,001,368	1,465,494	Nov 15 05:12 PM

Open in Screener

HALO

Halozyme Therapeutics Inc.

May 03 • 04:00PM ET

39.91

Dollar change +0.09
Percentage change 0.23	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

HALO Halozyme Therapeutics Inc. daily Stock Chart

Held by: VTI IJH VB IWM VXF VBK IWO FBT IBB IJK

Index	RUT	P/E	18.92	EPS (ttm)	2.11	Insider Own	1.11%	Shs Outstand	126.77M	Perf Week	3.47%
Market Cap	5.07B	Forward P/E	8.97	EPS next Y	4.45	Insider Trans	-7.84%	Shs Float	125.65M	Perf Month	0.45%
Income	281.59M	PEG	0.76	EPS next Q	0.69	Inst Own	98.81%	Short Float	6.56%	Perf Quarter	18.50%
Sales	829.25M	P/S	6.11	EPS this Y	27.24%	Inst Trans	3.74%	Short Ratio	8.22	Perf Half Y	19.10%
Book/sh	0.66	P/B	60.37	EPS next Y	26.26%	ROA	15.75%	Short Interest	8.24M	Perf Year	23.18%
Cash/sh	2.64	P/C	15.09	EPS next 5Y	25.00%	ROE	222.07%	52W Range	29.85 - 45.00	Perf YTD	7.98%
Dividend Est.	-	P/FCF	13.58	EPS past 5Y	-	ROI	17.79%	52W High	-11.31%	Beta	1.25
Dividend TTM	-	Quick Ratio	5.50	Sales past 5Y	41.16%	Gross Margin	67.91%	52W Low	33.70%	ATR (14)	1.06
Dividend Ex-Date	-	Current Ratio	6.64	EPS Y/Y TTM	44.87%	Oper. Margin	40.71%	RSI (14)	55.93	Volatility	3.32% 2.52%
Employees	373	Debt/Eq	18.27	Sales Y/Y TTM	25.62%	Profit Margin	33.96%	Recom	1.36	Target Price	50.50
Option/Short	Yes / Yes	LT Debt/Eq	17.89	EPS Q/Q	56.52%	Payout	0.00%	Rel Volume	0.90	Prev Close	39.82
Sales Surprise	-0.42%	EPS Surprise	2.68%	Sales Q/Q	26.75%	Earnings	May 07 AMC	Avg Volume	1.00M	Price	39.91
SMA20	2.37%	SMA50	-0.19%	SMA200	2.81%	Trades		Volume	902,798	Change	0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39
Feb-05-20	Upgrade	Piper Sandler	Neutral → Overweight	$18 → $27
Jan-09-20	Upgrade	BMO Capital Markets	Market Perform → Outperform	$17 → $24
Jan-08-20	Initiated	Goldman	Buy	$24

Show Previous Ratings

May-03-24 04:17AM	How Novo-Catalent Deal Affects Halozyme (HALO)? (Insider Monkey)
Apr-30-24 10:01AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-25-24 04:45PM	Mahesh Krishnan Elected to Halozyme's Board of Directors (PR Newswire)
06:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition (InvestorPlace)
Apr-24-24 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
08:30AM	Loading…
Apr-23-24 08:30AM	Halozyme to Report First Quarter 2024 Financial and Operating Results (PR Newswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-04-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Mar-29-24 06:40AM	The 3 Best Biotech Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-21-24 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report? (Zacks)
Mar-19-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Mar-14-24 01:24AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
02:05AM	Loading…
Mar-12-24 02:05AM	Should You Hold Halozyme Therapeutics (HALO)? (Insider Monkey)
Mar-09-24 01:07PM	5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 03:15AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ... (GuruFocus.com)
Feb-27-24 08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-21-24 11:26AM	Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag (Zacks) +6.56%
09:00AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 05:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics (Zacks)
05:10PM	Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates (Zacks)
04:36PM	Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ... (GuruFocus.com)
04:15PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Feb-14-24 09:15AM	Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
06:49AM	Halozyme Therapeutics (HALO) Underperformed Despite Strong Outlook (Insider Monkey)
Feb-13-24 10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
04:30PM	Loading…
Feb-08-24 04:30PM	Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results (PR Newswire)
Jan-29-24 04:15PM	Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Jan-26-24 09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Jan-25-24 05:29PM	3 Biotech Stocks to Sell in January Before They Crash and Burn (InvestorPlace)
Jan-24-24 12:10PM	Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-22-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jan-18-24 05:01PM	Halozyme Therapeutics Inc's SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares (GuruFocus.com)
08:30AM	Halozyme Announces argenx Received Approval in Japan for VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE for Generalized Myasthenia Gravis (PR Newswire)
Jan-17-24 04:01AM	Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jan-16-24 08:15AM	Halozyme Announces Takeda Receives FDA Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire) +5.61%
01:15AM	Halozyme Announces Roche Receives European Commission Approval of Tecentriq SC with ENHANZE Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types (PR Newswire)
Jan-12-24 09:25AM	Halozyme to Host Investor Business Forum and Long-Term Outlook Call (PR Newswire)
Jan-10-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Dec-15-23 03:01PM	Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ... (GuruFocus.com)
Dec-14-23 12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks) -6.29%
Dec-08-23 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Dec-06-23 11:30AM	Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report? (Zacks)
Dec-05-23 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-27-23 08:00AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Nov-20-23 12:45PM	Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now (Zacks)
Nov-17-23 07:03AM	Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ... (GuruFocus.com)
Nov-16-23 09:55AM	Can Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
09:00AM	Halozyme Announces argenx Receives European Commission Approval of VYVGART SC with ENHANZE for Generalized Myasthenia Gravis (PR Newswire)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace)
04:43PM	Under the Microscope: 3 Biotech Stocks Pioneering Tomorrows Cures (InvestorPlace)
Nov-08-23 05:19AM	3 Promising Biotech Stocks Flying Under the Radar (InvestorPlace) -5.28%
Nov-07-23 11:22AM	Q3 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.04%
11:21AM	Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag (Zacks)
11:06AM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 06:00PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics (Zacks)
05:25PM	Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates (Zacks)
05:10PM	Halozyme Therapeutics Inc (HALO) Reports 15% YoY Increase in Q3 Royalty Revenue, Raises 2023 ... (GuruFocus.com)
04:27PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
07:30AM	Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE Technology in Alzheimer's Disease (PR Newswire)
Oct-30-23 06:35PM	Halozyme To Report Third Quarter 2023 Financial and Operating Results (PR Newswire)
Oct-27-23 08:47AM	Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune (InvestorPlace)
Oct-20-23 12:08PM	12 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
05:36AM	Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals (Zacks)
Oct-19-23 07:32AM	UPDATE 2-Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial (Reuters)
07:15AM	Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma (PR Newswire)
Oct-18-23 05:01AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ... (GuruFocus.com)
Oct-16-23 03:05PM	Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference (PR Newswire)
08:00AM	Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery (PR Newswire)
Oct-13-23 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Sep-20-23 05:01AM	Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ... (GuruFocus.com)
Sep-07-23 11:30AM	Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound? (Zacks)
09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Sep-05-23 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Sep-01-23 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-31-23 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-30-23 07:17AM	Should You Remain Confident in Halozyme Therapeutics (HALO)? (Insider Monkey)
Aug-29-23 04:50AM	Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain (PR Newswire)
Aug-09-23 12:19PM	Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised (Zacks)
Aug-08-23 09:00PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
05:40PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates (Zacks)
04:32PM	Halozyme Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS (PR Newswire)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Jul-28-23 12:00PM	15 Best Russell 2000 Stocks To Buy Now (Insider Monkey)
06:14AM	Drugmakers go under the skin, skirting early US Medicare price negotiations (Reuters)
06:00AM	FOCUS-Drugmakers go under the skin, skirting early US Medicare price negotiations (Reuters)
Jul-25-23 08:30AM	Halozyme To Report Second Quarter 2023 Financial and Operating Results (PR Newswire)
Jul-18-23 05:39AM	Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-17-23 01:15AM	Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire) +5.36%
Jul-14-23 10:56AM	Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study (Zacks)
Jul-13-23 01:15AM	Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis (PR Newswire) +5.43%
Jun-27-23 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jun-26-23 07:08AM	Should You Hold Halozyme Therapeutics (HALO)? (Insider Monkey)
Jun-21-23 08:00PM	HALO: Raising target price to $38.00 (Argus Research)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Sale	38.35	10,000	383,500	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 26 '24	Option Exercise	11.20	11,618	130,160	168,176	Mar 26 07:38 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Option Exercise	10.66	10,000	106,638	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Sale	42.27	10,000	422,730	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Option Exercise	12.07	10,000	120,700	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Sale	41.64	10,000	416,370	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Option Exercise	8.11	7,471	60,590	164,029	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Sale	39.55	10,000	395,463	156,558	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '24	Sale	39.95	10,000	399,460	159,087	Feb 28 06:49 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '24	Option Exercise	0.00	37,884	0	685,814	Feb 20 06:49 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Feb 16 '24	Option Exercise	0.00	4,796	0	14,257	Feb 20 06:55 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,422	0	18,344	Feb 20 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,376	0	171,247	Feb 20 06:59 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '24	Option Exercise	0.00	3,386	0	160,529	Feb 16 05:47 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '24	Option Exercise	0.00	1,254	0	11,345	Feb 16 05:41 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '24	Option Exercise	0.00	13,092	0	651,096	Feb 16 05:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 10 '24	Option Exercise	0.00	31,281	0	654,947	Feb 13 04:12 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 10 '24	Option Exercise	0.00	2,502	0	11,568	Feb 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 10 '24	Option Exercise	0.00	8,133	0	160,044	Feb 13 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 17 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Option Exercise	12.07	10,000	120,700	161,911	Jan 18 04:07 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jan 16 '24	Sale	36.00	10,000	360,000	151,911	Jan 18 04:07 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Jan 03 '24	Option Exercise	0.00	7,611	0	12,418	Jan 05 04:04 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Option Exercise	12.07	10,000	120,700	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 13 '23	Sale	40.39	10,000	403,940	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Option Exercise	13.55	10,000	135,547	161,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Dec 12 '23	Sale	39.63	10,000	396,322	151,911	Dec 13 07:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Option Exercise	13.81	10,000	138,100	161,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 15 '23	Sale	39.79	10,000	397,880	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Option Exercise	14.32	10,000	143,173	160,203	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Nov 14 '23	Sale	39.08	10,000	390,790	151,911	Nov 16 04:18 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Option Exercise	19.98	10,000	199,800	161,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 17 '23	Sale	36.52	10,000	365,200	151,911	Oct 17 07:28 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Option Exercise	19.98	10,000	199,800	161,911	Sep 19 04:09 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 19 '23	Sale	39.10	10,000	390,980	151,911	Sep 19 04:09 PM
Torley Helen	PRESIDENT AND CEO	Aug 31 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 31 '23	Sale	42.82	10,000	428,170	623,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 30 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 30 '23	Sale	42.85	10,000	428,540	623,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 29 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 31 05:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 29 '23	Sale	42.40	10,000	424,020	623,666	Aug 31 05:35 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 22 '23	Option Exercise	19.68	10,000	196,778	159,986	Aug 23 05:08 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 22 '23	Sale	42.41	10,000	424,070	151,911	Aug 23 05:08 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '23	Sale	43.18	10,000	431,820	623,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 16 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 16 '23	Sale	43.53	10,000	435,320	623,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '23	Option Exercise	13.87	10,000	138,700	633,666	Aug 17 05:29 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '23	Sale	43.77	10,000	437,680	623,666	Aug 17 05:29 PM
Daly James M	Director	Aug 14 '23	Sale	43.74	10,000	437,410	20,503	Aug 15 04:04 PM
Daly James M	Director	Aug 11 '23	Sale	43.71	10,000	437,110	30,503	Aug 15 04:04 PM
Torley Helen	PRESIDENT AND CEO	Jul 27 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 27 '23	Sale	43.79	10,000	437,900	623,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 26 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 26 '23	Sale	42.69	10,000	426,890	623,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 25 '23	Option Exercise	13.87	10,000	138,700	633,666	Jul 27 04:03 PM
Torley Helen	PRESIDENT AND CEO	Jul 25 '23	Sale	42.80	10,000	427,960	623,666	Jul 27 04:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 18 '23	Option Exercise	15.30	20,000	306,098	151,911	Jul 19 04:10 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 18 '23	Sale	40.43	10,000	404,300	141,911	Jul 19 04:10 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 21 '23	Option Exercise	18.41	10,000	184,100	151,911	Jun 22 06:20 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 21 '23	Sale	36.00	10,000	360,000	141,911	Jun 22 06:20 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

MDGL

Madrigal Pharmaceuticals Inc

HALO

Halozyme Therapeutics Inc.

Upgrade your FINVIZ experience